Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib

COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Takeshima, Tappei, Miyoshi, Yasuhide, Nakaigawa, Noboru, Yao, Masahiro, Tanabe, Mikiko, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696783/
https://www.ncbi.nlm.nih.gov/pubmed/31427949
http://dx.doi.org/10.1159/000501716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696783/
https://www.ncbi.nlm.nih.gov/pubmed/31427949
http://dx.doi.org/10.1159/000501716

Ejemplares similares